Overview Recently Resected Patient Continuing Adjuvant Therapy Recurrence Post Adjuvant Therapy Metastatic Patient With Progression After GI/Surgeon Diagnosis About GIST
Print
Font size:

GLIVEC: REVOLUTIONIZING THE TREATMENT OF KIT+ GIST

Prior to GLIVEC, the prognosis for patients with gastrointestinal stromal tumor (GIST) was poor. Tumor recurrence often followed surgical resection for primary disease. In advanced disease, there were no effective treatment options and survival averaged about 1 year.1,2

Today, adjuvant treatment with GLIVEC is significantly reducing the risk of recurrence following surgery for patients with primary KIT+ GIST. And, in the treatment of advanced KIT+ GIST, GLIVEC is extending the lives of patients to a median of nearly 5 years, even in the face of disease progression.3,4,5

GLIVEC: Positively Impacting the Lives of KIT+ GIST Patients

The patient cases to the right illustrate important clinical decision points in KIT+ GIST. Visit them to view information that can help you make informed treatment choices for your patients.

Select case now.

Prescribing GLIVEC

Review the safety profile of GLIVEC here, while getting the basics on dosing, administration, and ways to manage potential side effects.

Prescribing GLIVEC

About GIST

Learn more about GIST from its cellular origins through its clinical course, and see why a multidisciplinary approach optimizes patient care.



Recently Resected
Patient

Learn More Recently Resected Patient Image
Continuing Adjuvant Therapy Patient Image

Continuing
Adjuvant Therapy

Learn More
Recurrence Post Adjuvant Therapy Patient Image

Recurrence Post
Adjuvant Therapy

Learn More
Metastatic Patient With Progression Patient Image

Metastatic Patient
With Progression

Learn More
After GI/Surgeon Diagnosis Patient Image

After GI/Surgeon
Diagnosis

Learn More

Summary of Product
Characteristics

View more

Safety
Information

Learn more

Glivec and KIT+ Gist

Glivec and Ph+ CML

Glivec and Additional Indications

For Your Patients

Library and Tools